Long-term survival of ANCA-associated vasculitis

Long-term survival of ANCA-associated vasculitis

Bibliographic Details
Main Authors:	Flossmann, O, Berden, A, De Groot, K, Harper, L, Heijl, C, HOGlund, P, Jayne, D, Luqmani, R, Mahr, A, Mukhtyar, C, Pusey, C, Rasmussen, N, Westman, K
Format:	Journal article
Published:	2009

Similar Items

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
by: Robson, J, et al.
Published: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
by: Robson, J, et al.
Published: (2015)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. A European, multi-centre randomized controlled trial: long-term follow-up
by: Harper, L, et al.
Published: (2011)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
by: Harper, L, et al.
Published: (2012)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial
by: Harper, L, et al.
Published: (2009)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
by: Robson, J, et al.
Published: (2014)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
by: Yates, M, et al.
Published: (2016)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
by: Yates, M, et al.
Published: (2016)

The role of biologic therapies in the management of systemic vasculitis.
by: Chan, A, et al.
Published: (2006)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials
by: Walsh, M, et al.
Published: (2009)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
by: Yates, M, et al.
Published: (2016)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2008)

Development of comprehensive disease assessment in systemic vasculitis.
by: Flossmann, O, et al.
Published: (2007)

Long- term outcome of paediatric patients with ANCA vasculitis
by: Pusey Charles D, et al.
Published: (2011-06-01)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis
by: Luqmani, R, et al.
Published: (2007)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

The characterisation and determinants of quality of life in ANCA associated vasculitis
by: Basu, N, et al.
Published: (2014)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
by: Mukhtyar, C, et al.
Published: (2008)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
by: Yates, M, et al.
Published: (2017)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
by: Basu, N, et al.
Published: (2012)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
by: Jones, R, et al.
Published: (2009)